Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 4/20 | 0.43 |
| ▸ | RXRA | P19793 | 3/20 | 0.43 |
| ▸ | RXRG | P48443 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium SCHEMBL214696 | 0.99 | RXRB (0.42) | RXRBRXRARXRGNPC1RAB9A | |
| SCHEMBL214694 | 0.99 | RXRB (0.42) | RXRBRXRARXRGNPC1RAB9A | |
| SCHEMBL215438 | 0.99 | RXRB (0.42) | RXRBRXRARXRGNPC1RAB9A | |
| SCHEMBL215440 | 0.99 | RXRB (0.42) | RXRBRXRARXRGNPC1RAB9A | |
| SCHEMBL12361885 | 0.94 | RXRB (0.41) | RXRBRXRARXRGNPC1RAB9A | |
| SCHEMBL1645425 | 0.93 | RXRB (0.41) | RXRBRXRARXRGNPC1RAB9A | |
| Potassium Ion SCHEMBL214695 | 0.93 | RORC (0.37) | RXRBRXRARXRGNPC1RAB9A | |
| SCHEMBL215439 | 0.93 | RORC (0.37) | RXRBRXRARXRGNPC1RAB9A | |
| SCHEMBL213985 | 0.91 | RXRB (0.45) | RXRBRXRARXRGNPC1RAB9A | |
| SCHEMBL213408 | 0.90 | MCL1 (0.34) | RXRBRXRANPC1RAB9ATRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2123273-B1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | ONO PHARMACEUTICAL CO (JP) | 2013-10-23 | — | — | EP | claimed |
| EP-1612208-B1 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO (JP) | 2011-08-31 | — | — | EP | claimed |
| US-20100076038-A1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | claimed |
| US-7629369-B2 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICALS CO., LTD. (JP) | 2009-12-08 | — | — | US | claimed |
| EP-2123273-A1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | ONO Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | claimed |
| US-20080312326-A1 | Method for the Prevention and/or Treatment of Neurodegenerative Diseases Characterized by Administering and Ep1 Receptor Antagonist | THE JOHN HOPKINS UNIVERSITY (US) | 2008-12-18 | — | — | US | claimed |
| US-7335776-B2 | Remedies for depression containing EP1 antagonist as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-02-26 | — | — | US | claimed |
| US-20070167500-A1 | Remedy for urinary tract diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-19 | — | — | US | claimed |
| WO-2006135545-A2 | A METHOD FOR THE PREVENTION AND/OR TREATMENT OF NEURODEGENERATIVE DISEASES CHARACTERIZED BY ADMINISTERING AN EP1 RECEPTOR ANTAGONIST | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-12-21 | — | — | WO | claimed |
| EP-1642594-A1 | REMEDY FOR URINARY TRACT DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | claimed |
| US-20060030713-A1 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. | 2006-02-09 | — | — | US | claimed |
| EP-1612208-A2 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | claimed |
| US-20050124672-A1 | N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermediate for the compound and processes for producing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | claimed |
| US-20040082653-A1 | Remedies for depression containing ep1 antagonist as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | claimed |
| EP-1369419-A1 | N-PHENYLARYLSULFONAMIDE COMPOUND, DRUG CONTAINING THE COMPOUND AS ACTIVE INGREDIENT, INTERMEDIATE FOR THE COMPOUND, AND PROCESSES FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | claimed |
| EP-1369129-A1 | REMEDIES FOR DEPRESSION CONTAINING EP1 ANTAGONIST AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | claimed |
| CN-119367540-A | Application of cyclooxygenase type II inhibitor | 中国科学院广州生物医药与健康研究院 | 2025-01-28 | — | — | CN | disclosed |
| US-9181187-B2 | Therapeutic agent for urinary excretion disorder | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| EP-1369419-A1 | N-PHENYLARYLSULFONAMIDE COMPOUND, DRUG CONTAINING THE COMPOUND AS ACTIVE INGREDIENT, INTERMEDIATE FOR THE COMPOUND, AND PROCESSES FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |
| EP-1369129-A1 | REMEDIES FOR DEPRESSION CONTAINING EP1 ANTAGONIST AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030713-A1 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | PTGER1, PTGER2, PTGES | RXRB 1206/4885RXRA 1038/4885RXRG 1167/4885 |
| US-20080312326-A1 | Method for the Prevention and/or Treatment of Neurodegenerative Diseases Characterized by Administering and Ep1 Receptor Antagonist | PTGER1, PSEN1, EPN1 | RXRB 2072/4885RXRA 2044/4885RXRG 2232/4885 |
| US-20100076038-A1 | THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER | PTGER1, TMPRSS15, EPDR1 | RXRB 4498/4885RXRA 4540/4885RXRG 4625/4885 |
| US-20070167500-A1 | Remedy for urinary tract diseases | PTGER3, PTGER1, PTGES3 | RXRB 2069/4885RXRA 1946/4885RXRG 2245/4885 |
| US-20050124672-A1 | N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermediate for the compound and processes for producing the same | PTGER1, PTGER2, PTGES | RXRB 1279/4885RXRA 1048/4885RXRG 1299/4885 |
| US-20040082653-A1 | Remedies for depression containing ep1 antagonist as the active ingredient | PTGER1, PTGER2, PTGS1 | RXRB 1002/4885RXRA 763/4885RXRG 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.